Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keeps Outperform Rating

08/13/2021 | 09:38am EDT


ę MT Newswires 2021
All news about VYNE THERAPEUTICS INC.
10/26Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflamm..
PU
10/26VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/26Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflamm..
AQ
10/21VYNE THERAPEUTICS : Announces Formation of Scientific Advisory Board
AQ
10/19VYNE THERAPEUTICS : Enrolls First Patient in Trial of FMX114 to Treat Atopic Dermatitis; S..
MT
10/19VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of..
PU
10/19VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/19VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of..
AQ
10/19VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment o..
CI
10/05VYNE THERAPEUTICS : Partner Cutia Therapeutics Enrolls First Patient in Late-Stage Acne Dr..
MT
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 18,2 M - -
Net income 2021 -70,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,01x
Yield 2021 -
Capitalization 69,5 M 69,5 M -
Capi. / Sales 2021 3,81x
Capi. / Sales 2022 9,69x
Nbr of Employees 106
Free-Float 87,2%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,35 $
Average target price 6,67 $
Spread / Average Target 394%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-78.64%70
JOHNSON & JOHNSON5.32%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.17.22%244 227
ELI LILLY AND COMPANY47.15%225 231